APP and Alzheimer disease: To explore whether CPPs can attenuate behavioral impairments in the APP/PS1 AD mice model, we assessed the behavioral changes in 6.5-month-old wild-type (WT) and APP/PS1 mice, with or without the one-month daily intragastric (IG) administration of 100 and 300 mg/kg of CPPs, when normal saline served as vehicle control.